Abstract
PRP vaccination (vax) of 18 mo old children at high risk for contracting invasive Hib disease is recommended by the ACIP. The timing of revax of such children has not been studied. Thus far, 30 children have been stratified according to their postvax anti-PRP antibody (Ab) level (determined by radioantigen binding assay) following PRP vax at 18-20 mo then sequentially assigned to 3 groups with comparable distribution of Ab levels to receive revax at 24, 30 or 36 mo of age; each group had children who had failed to respond to primary vax with PRP (<30% rise in Ab titer). The geometric mean titer +/- the standard deviation, the % responding to revax (>30% rise in Ab titer), and the % with presumed protective postvax Ab level (defined as >1.0 μg/ml)for each vaccine group were as follows:
GMT's rose in both the 24-27 mo and the 30-33 mo groups; proportional rises were, as expected, more frequent in the latter. Adequate responses to revax were seen in some children who initially appeared to be “intrinsically” unresponsive to PRP vax.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pichichero, M., Bracikowski, A., Sullivan, R. et al. POLYRIBOSYLPHOSPHATE (PRP) REVACCINATION TO PREVENT INVASIVE HAEMOPHILUS INFLUENZAE B (HIB) IN CHILDREN FIRST IMMUNIZED AT 18–20 MOS OF AGE. Pediatr Res 21 (Suppl 4), 331 (1987). https://doi.org/10.1203/00006450-198704010-00986
Issue Date:
DOI: https://doi.org/10.1203/00006450-198704010-00986